Gabrail Cancer CTR Research
Welcome,         Profile    Billing    Logout  
 31 Trials 
76 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gabrail, Nashat Y
NCT05434663: Safety Study of Repeat Doses of SUSTOL in Adults

Active, not recruiting
4
300
US
SUSTOL, Granisetron extended-release injection for subcutaneous use
Heron Therapeutics
Chemotherapy-Induced Nausea and Vomiting (CINV)
10/25
10/25
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/25
06/26
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
OnTARGET, NCT04538625: Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

Completed
3
287
US, RoW
Crofelemer 125 MG [Mytesi], Placebo
Napo Pharmaceuticals, Inc.
Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
08/23
10/23
NCT03671044: A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Recruiting
3
657
US, RoW
Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2)
Jina Pharmaceuticals Inc., Intas Pharmaceuticals, Ltd., Lambda Therapeutic Research Ltd.
Triple Negative Breast Cancer
05/25
12/25
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
HLX10-020-SCLC302, NCT05353257 / 2022-002226-27: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active, not recruiting
3
511
Europe, US, RoW
HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.
Limited-Stage Small Cell Lung Cancer
07/25
12/26
NCT01954992: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Recruiting
3
480
US
Glufosfamide, Fluorouracil, 5-FU
Eleison Pharmaceuticals LLC.
Metastatic Pancreatic Adenocarcinoma
06/26
12/26
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
01/26
06/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
VAYHIA, NCT05648968: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Recruiting
3
90
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals
Warm Autoimmune Hemolytic Anemia (wAIHA)
03/26
05/29
REZILIENT3, NCT05973773: (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Recruiting
3
272
Europe, Canada, Japan, US, RoW
TAS6417, Zipalertinib, CLN-081
Taiho Oncology, Inc.
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
07/26
08/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT05645107: A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants with HGG and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Recruiting
3
386
Europe, US, RoW
Xembify, Immune Globulin Subcutaneous (Human), 20% (IGSC 20%), Placebo, 0.9% Normal Saline
Grifols Therapeutics LLC
Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
05/26
06/26
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Completed
2
61
US
GT0918, proxalutamide, androgen receptor antagonist
Suzhou Kintor Pharmaceutical Inc,
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
03/22
09/22
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Active, not recruiting
2
170
US, RoW
OQL011, Vehicle Ointment
OnQuality Pharmaceuticals (USA) LLC
Hand-Foot Skin Reaction (HFSR)
02/24
06/24
NCT06281678: A Study of IBI363 in Subjects with Advanced Solid Malignancies

Recruiting
2
178
US
IBI363
Innovent Biologics (Suzhou) Co. Ltd.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
03/26
12/26
FID-007-003, NCT06332092: FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
2
46
US
FID007, Paclitaxel in Polyethyloxazoline Polymer; FID-007; FID007 (CN); FID 007; Nanoencapsulated Paclitaxel FID-007
Fulgent Pharma LLC.
Head and Neck Squamous Cell Carcinoma
03/25
12/25
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Active, not recruiting
2
41
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen, a wholly owned subsidiary of Pfizer
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
07/24
09/25
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
KEYNOTE B36, NCT04892472: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
2
100
US
NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
NovoCure GmbH, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/24
12/26
NCT06568692: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Recruiting
2
90
US
PCS6422 and capecitabine, Capecitabine
Processa Pharmaceuticals
Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
09/26
10/26
HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting
2
90
Japan, US, RoW
LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Lantern Pharma Inc.
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
12/25
06/26
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

Withdrawn
2
80
Europe, RoW
YH001 + Toripalimab
Eucure (Beijing) Biopharma Co., Ltd
HCC, NSCLC Stage IIIB, NSCLC Stage IV
12/24
03/25
NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Active, not recruiting
2
66
Europe, US
Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan
Taiho Oncology, Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
07/25
01/27
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Recruiting
2
120
Europe, Japan, US, RoW
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
12/26
12/26
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
Cornerstone001, NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
2
10
US, RoW
AST-301(pNGVL3-hICD), AST-301, rhuGM-CSF, Leukine, Sargramostim, Placebo, Normal Saline, Pembrolizumab, Keytruda, Capecitabine, Xeloda
Aston Sci. Inc.
Breast Cancer
05/24
05/24
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Active, not recruiting
2
122
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
KEYNOTE B84, NCT04815720: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Checkmark P1b data in combination with pepinemab for recurrent or metastatic HNSCC
Apr 2022 - Apr 2022: P1b data in combination with pepinemab for recurrent or metastatic HNSCC
Completed
1/2
49
US
pepinemab + pembrolizumab, KEYTRUDA®
Vaccinex Inc., Merck Sharp & Dohme LLC
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
07/24
07/24
NCT05255484: Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Terminated
1/2
24
US
LM-108, An Anti-PD-1 Antibody
LaNova Medicines Limited
Advanced Solid Tumor
10/23
10/23
BA3071-001, NCT05180799: A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Recruiting
1/2
320
US, RoW
BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
BioAtla, Inc.
NSCLC, Melanoma
12/25
06/26
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Active, not recruiting
1/2
81
Europe, US, RoW
Orelabrutinib (ICP-022)
Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
12/23
01/25
NCT05785728: A Study of DB-1202 Monotherapy in Advanced Solid Tumors

Not yet recruiting
1/2
150
RoW
DB-1202
DualityBio Inc.
Advanced Solid Tumor
02/24
02/24
NCT05271292: Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Recruiting
1/2
36
US
Chiauranib, CS2164
Chipscreen Biosciences, Ltd.
Small Cell Lung Cancer, Advanced Solid Malignant Tumor
03/25
05/25
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
MRG004A-001, NCT04843709: A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Recruiting
1/2
181
US, RoW
MRG004A
Shanghai Miracogen Inc.
Advanced or Metastatic Solid Tumors
04/24
06/25
NCT06087653: Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Recruiting
1/2
6
US
Lenalidomide, Bortezomib, Dexamethasone
Starton Therapeutics, Inc
Multiple Myeloma
07/24
09/24
NCT05320198: Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia

Recruiting
1/2
150
US
DISC-0974
Disc Medicine, Inc
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
09/26
09/26
NCT06669117: FIH Trial of VERT-002 in Patients with Locally Advanced or Metastatic Solid Tumors with MET Alterations

Recruiting
1/2
140
Europe, US, RoW
VERT-002
Pierre Fabre Medicament
Solid Tumor, MET Alteration
10/30
10/32
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
01/26
03/26
LB-SA53-101, NCT06578624: Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
70
US
SA53-OS (phase 1), SA53-OS (phase 2)
Lamassu Bio Inc
Solid Tumor
03/26
12/28
INDP-D101, NCT05651022: Study of DECOY20 with or Without Tislelizumab in Patients with Advanced Solid Tumors

Recruiting
1/2
120
US
Decoy20, Tislelizumab
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
06/27
09/27
OPAL, NCT04329728: The Study: AVM0703 for Treatment of Lymphoid Malignancies

Recruiting
1/2
144
US
AVM0703, Supra-Pharmacologic Dexamethasone Phosphate
AVM Biotechnology Inc, Medpace, Inc.
Lymphoid Malignancies
04/25
06/25
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
1123
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
NCT05944276: A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
71
US
HB0045 Drug Product, fixed dose combination of two antibodies targeting two different epitopes (N-terminal and catalytic site) of CD73
Huabo Biopharm Co., Ltd., Gabrail Cancer Center Research, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center
Solid Tumor, Adult
08/25
03/26
NCT06056323: A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Recruiting
1/2
71
US
HB0045 Drug Product, fixed dose combination of two antibodies targeting two different epitopes (N-terminal and catalytic site) of CD73
Shanghai Huaota Biopharmaceutical Co., Ltd., Gabrail Cancer Center Research, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center
Solid Tumor, Adult
09/25
03/26
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
INX-315-01, NCT05735080: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Recruiting
1/2
90
US, RoW
INX-315, Fulvestrant, faslodex
Incyclix Bio
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
12/25
06/26
ASIST, NCT05322590: BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Active, not recruiting
1/2
195
US
BXQ-350, SapC-DOPS, Placebo
Bexion Pharmaceuticals, Inc., ICON plc, CTI Clinical Trial and Consulting Services
Metastatic Colorectal Carcinoma, Neuropathy
04/26
04/29
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT04683354: Study of HL-085 in Patients With Advanced Solid Tumor Tumors

Completed
1
28
US
HL-085
Kechow Pharma, Inc.
Solid Tumor, Adult
09/22
12/22
Study 1100, NCT03589339: NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy

Recruiting
1
145
US
NBTXR3, SABR, Stereotaxic Ablative Radiotherapy, Stereotaxic Body Radiation Therapy, Nivolumab, Opdivo, Pembrolizumab, Keytruda
Nanobiotix
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis from Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis from Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis from Malignant Melanoma of Skin (disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis from Malignant Tumor of Bladder (Disorder)
04/27
05/28
NCT04865159: Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

Terminated
1
6
US
Tipifarnib
Kura Oncology, Inc.
Advanced Solid Tumor
05/23
05/23
KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients with HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
85
US
CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab
Cue Biopharma, Merck Sharp & Dohme LLC
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
01/26
01/26
NCT06130722: First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Recruiting
1
18
US
FL115
Suzhou Forlong Biotechnology Co.,Ltd,
Locally Advanced/Metastatic Solid Tumors
05/25
09/25
SHR-A1811-I-101, NCT04446260: A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Active, not recruiting
1
396
US, RoW
SHR-A1811
Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd.
Advanced Solid Tumors
12/25
03/26
NKT3447-101, NCT06264921: A Study with NKT3447 for Adults with Advanced/Metastatic Solid Tumors

Active, not recruiting
1
90
US
NKT3447
NiKang Therapeutics, Inc.
Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
11/25
03/27
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
82
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
07/26
12/26
HBI-2376-101, NCT05163028: A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Recruiting
1
42
US
HBI-2376
HUYABIO International, LLC.
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
12/24
12/24
CUE-102-01, NCT05360680: A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Completed
1
42
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
03/25
03/25
NCT05293912: SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Terminated
1
2
US
SG2501, Recombinant Anti-cluster of Differentiation 38(CD38)/47(CD47) Bispecific Antibody
Hangzhou Sumgen Biotech Co., Ltd.
Hematological Malignancy, Lymphoma
06/23
06/23
SGR-1505-101, NCT05544019: Study of SGR-1505 in Mature B-Cell Neoplasms

Recruiting
1
52
US, RoW
SGR-1505
Schrödinger, Inc.
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
03/26
03/26
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Recruiting
1
169
US, RoW
ABSK121-NX
Abbisko Therapeutics Co, Ltd
Solid Tumor
03/25
06/25
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
NCT05828303: A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Withdrawn
1
12
Europe, US, RoW
TPX-0005, repotrectinib, Metformin Hydrochloride, Glucophage, Metabet, Glucient, Diagemet, Axpinet, Digoxin, Lanoxin, Rosuvastatin Calcium, Crestor
Turning Point Therapeutics, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
07/25
11/25
NCT05485974: A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Recruiting
1
44
US
HBI-2438
HUYABIO International, LLC.
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
08/25
08/25
NCT05828277: A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

Withdrawn
1
24
Europe, US
repotrectinib (TPX-0005), Oral TPX-0005 capsules, repotrectinib
Turning Point Therapeutics, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
08/25
12/25
NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Terminated
1
22
US
CHS-006 (anti-TIGIT), JS006, toripalimab (anti-PD-1), CHS-007, TAB001, JS001
Coherus Biosciences, Inc., Medpace, Inc., Shanghai Junshi Bioscience Co., Ltd.
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
07/24
07/24
ON-5001, NCT06022029: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Recruiting
1
168
US, RoW
ONM-501, Cemiplimab, Libtayo
OncoNano Medicine, Inc.
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
04/26
08/26
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease

Active, not recruiting
N/A
12000
Europe, US
Low-dose CT scan
Guardant Health, Inc.
Lung Cancer
12/25
12/25
CYBRID-01, NCT05478538: Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Recruiting
N/A
200
US
Core Needle or Forceps Biopsy
Elephas, Beaufort CRO
Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
12/26
12/26
Dunn, Brittany
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gabrail, Nashat Y
NCT05434663: Safety Study of Repeat Doses of SUSTOL in Adults

Active, not recruiting
4
300
US
SUSTOL, Granisetron extended-release injection for subcutaneous use
Heron Therapeutics
Chemotherapy-Induced Nausea and Vomiting (CINV)
10/25
10/25
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/25
06/26
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
OnTARGET, NCT04538625: Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

Completed
3
287
US, RoW
Crofelemer 125 MG [Mytesi], Placebo
Napo Pharmaceuticals, Inc.
Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
08/23
10/23
NCT03671044: A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Recruiting
3
657
US, RoW
Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2)
Jina Pharmaceuticals Inc., Intas Pharmaceuticals, Ltd., Lambda Therapeutic Research Ltd.
Triple Negative Breast Cancer
05/25
12/25
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
HLX10-020-SCLC302, NCT05353257 / 2022-002226-27: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Active, not recruiting
3
511
Europe, US, RoW
HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.
Limited-Stage Small Cell Lung Cancer
07/25
12/26
NCT01954992: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Recruiting
3
480
US
Glufosfamide, Fluorouracil, 5-FU
Eleison Pharmaceuticals LLC.
Metastatic Pancreatic Adenocarcinoma
06/26
12/26
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
01/26
06/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
VAYHIA, NCT05648968: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Recruiting
3
90
Europe, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals
Warm Autoimmune Hemolytic Anemia (wAIHA)
03/26
05/29
REZILIENT3, NCT05973773: (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Recruiting
3
272
Europe, Canada, Japan, US, RoW
TAS6417, Zipalertinib, CLN-081
Taiho Oncology, Inc.
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
07/26
08/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT05645107: A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants with HGG and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Recruiting
3
386
Europe, US, RoW
Xembify, Immune Globulin Subcutaneous (Human), 20% (IGSC 20%), Placebo, 0.9% Normal Saline
Grifols Therapeutics LLC
Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
05/26
06/26
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Completed
2
61
US
GT0918, proxalutamide, androgen receptor antagonist
Suzhou Kintor Pharmaceutical Inc,
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
03/22
09/22
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Active, not recruiting
2
170
US, RoW
OQL011, Vehicle Ointment
OnQuality Pharmaceuticals (USA) LLC
Hand-Foot Skin Reaction (HFSR)
02/24
06/24
NCT06281678: A Study of IBI363 in Subjects with Advanced Solid Malignancies

Recruiting
2
178
US
IBI363
Innovent Biologics (Suzhou) Co. Ltd.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
03/26
12/26
FID-007-003, NCT06332092: FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
2
46
US
FID007, Paclitaxel in Polyethyloxazoline Polymer; FID-007; FID007 (CN); FID 007; Nanoencapsulated Paclitaxel FID-007
Fulgent Pharma LLC.
Head and Neck Squamous Cell Carcinoma
03/25
12/25
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Active, not recruiting
2
41
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen, a wholly owned subsidiary of Pfizer
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
07/24
09/25
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
KEYNOTE B36, NCT04892472: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
2
100
US
NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
NovoCure GmbH, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/24
12/26
NCT06568692: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Recruiting
2
90
US
PCS6422 and capecitabine, Capecitabine
Processa Pharmaceuticals
Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
09/26
10/26
HARMONIC, NCT05456256: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma

Recruiting
2
90
Japan, US, RoW
LP-300, Tavocept, BNP7787, Dimesna, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Lantern Pharma Inc.
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung
12/25
06/26
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

Withdrawn
2
80
Europe, RoW
YH001 + Toripalimab
Eucure (Beijing) Biopharma Co., Ltd
HCC, NSCLC Stage IIIB, NSCLC Stage IV
12/24
03/25
NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Active, not recruiting
2
66
Europe, US
Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan
Taiho Oncology, Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
07/25
01/27
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Recruiting
2
120
Europe, Japan, US, RoW
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
12/26
12/26
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
Cornerstone001, NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
2
10
US, RoW
AST-301(pNGVL3-hICD), AST-301, rhuGM-CSF, Leukine, Sargramostim, Placebo, Normal Saline, Pembrolizumab, Keytruda, Capecitabine, Xeloda
Aston Sci. Inc.
Breast Cancer
05/24
05/24
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Active, not recruiting
2
122
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
KEYNOTE B84, NCT04815720: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Checkmark P1b data in combination with pepinemab for recurrent or metastatic HNSCC
Apr 2022 - Apr 2022: P1b data in combination with pepinemab for recurrent or metastatic HNSCC
Completed
1/2
49
US
pepinemab + pembrolizumab, KEYTRUDA®
Vaccinex Inc., Merck Sharp & Dohme LLC
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
07/24
07/24
NCT05255484: Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Terminated
1/2
24
US
LM-108, An Anti-PD-1 Antibody
LaNova Medicines Limited
Advanced Solid Tumor
10/23
10/23
BA3071-001, NCT05180799: A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Recruiting
1/2
320
US, RoW
BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
BioAtla, Inc.
NSCLC, Melanoma
12/25
06/26
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Active, not recruiting
1/2
81
Europe, US, RoW
Orelabrutinib (ICP-022)
Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
12/23
01/25
NCT05785728: A Study of DB-1202 Monotherapy in Advanced Solid Tumors

Not yet recruiting
1/2
150
RoW
DB-1202
DualityBio Inc.
Advanced Solid Tumor
02/24
02/24
NCT05271292: Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Recruiting
1/2
36
US
Chiauranib, CS2164
Chipscreen Biosciences, Ltd.
Small Cell Lung Cancer, Advanced Solid Malignant Tumor
03/25
05/25
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
MRG004A-001, NCT04843709: A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Recruiting
1/2
181
US, RoW
MRG004A
Shanghai Miracogen Inc.
Advanced or Metastatic Solid Tumors
04/24
06/25
NCT06087653: Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Recruiting
1/2
6
US
Lenalidomide, Bortezomib, Dexamethasone
Starton Therapeutics, Inc
Multiple Myeloma
07/24
09/24
NCT05320198: Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia

Recruiting
1/2
150
US
DISC-0974
Disc Medicine, Inc
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
09/26
09/26
NCT06669117: FIH Trial of VERT-002 in Patients with Locally Advanced or Metastatic Solid Tumors with MET Alterations

Recruiting
1/2
140
Europe, US, RoW
VERT-002
Pierre Fabre Medicament
Solid Tumor, MET Alteration
10/30
10/32
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
01/26
03/26
LB-SA53-101, NCT06578624: Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
70
US
SA53-OS (phase 1), SA53-OS (phase 2)
Lamassu Bio Inc
Solid Tumor
03/26
12/28
INDP-D101, NCT05651022: Study of DECOY20 with or Without Tislelizumab in Patients with Advanced Solid Tumors

Recruiting
1/2
120
US
Decoy20, Tislelizumab
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
06/27
09/27
OPAL, NCT04329728: The Study: AVM0703 for Treatment of Lymphoid Malignancies

Recruiting
1/2
144
US
AVM0703, Supra-Pharmacologic Dexamethasone Phosphate
AVM Biotechnology Inc, Medpace, Inc.
Lymphoid Malignancies
04/25
06/25
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
1123
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
NCT05944276: A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
71
US
HB0045 Drug Product, fixed dose combination of two antibodies targeting two different epitopes (N-terminal and catalytic site) of CD73
Huabo Biopharm Co., Ltd., Gabrail Cancer Center Research, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center
Solid Tumor, Adult
08/25
03/26
NCT06056323: A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Recruiting
1/2
71
US
HB0045 Drug Product, fixed dose combination of two antibodies targeting two different epitopes (N-terminal and catalytic site) of CD73
Shanghai Huaota Biopharmaceutical Co., Ltd., Gabrail Cancer Center Research, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center
Solid Tumor, Adult
09/25
03/26
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
INX-315-01, NCT05735080: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Recruiting
1/2
90
US, RoW
INX-315, Fulvestrant, faslodex
Incyclix Bio
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
12/25
06/26
ASIST, NCT05322590: BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Active, not recruiting
1/2
195
US
BXQ-350, SapC-DOPS, Placebo
Bexion Pharmaceuticals, Inc., ICON plc, CTI Clinical Trial and Consulting Services
Metastatic Colorectal Carcinoma, Neuropathy
04/26
04/29
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT04683354: Study of HL-085 in Patients With Advanced Solid Tumor Tumors

Completed
1
28
US
HL-085
Kechow Pharma, Inc.
Solid Tumor, Adult
09/22
12/22
Study 1100, NCT03589339: NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy

Recruiting
1
145
US
NBTXR3, SABR, Stereotaxic Ablative Radiotherapy, Stereotaxic Body Radiation Therapy, Nivolumab, Opdivo, Pembrolizumab, Keytruda
Nanobiotix
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis from Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis from Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis from Malignant Melanoma of Skin (disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis from Malignant Tumor of Bladder (Disorder)
04/27
05/28
NCT04865159: Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

Terminated
1
6
US
Tipifarnib
Kura Oncology, Inc.
Advanced Solid Tumor
05/23
05/23
KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients with HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
85
US
CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab
Cue Biopharma, Merck Sharp & Dohme LLC
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
01/26
01/26
NCT06130722: First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Recruiting
1
18
US
FL115
Suzhou Forlong Biotechnology Co.,Ltd,
Locally Advanced/Metastatic Solid Tumors
05/25
09/25
SHR-A1811-I-101, NCT04446260: A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Active, not recruiting
1
396
US, RoW
SHR-A1811
Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd.
Advanced Solid Tumors
12/25
03/26
NKT3447-101, NCT06264921: A Study with NKT3447 for Adults with Advanced/Metastatic Solid Tumors

Active, not recruiting
1
90
US
NKT3447
NiKang Therapeutics, Inc.
Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
11/25
03/27
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
82
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
07/26
12/26
HBI-2376-101, NCT05163028: A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Recruiting
1
42
US
HBI-2376
HUYABIO International, LLC.
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
12/24
12/24
CUE-102-01, NCT05360680: A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Completed
1
42
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
03/25
03/25
NCT05293912: SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

Terminated
1
2
US
SG2501, Recombinant Anti-cluster of Differentiation 38(CD38)/47(CD47) Bispecific Antibody
Hangzhou Sumgen Biotech Co., Ltd.
Hematological Malignancy, Lymphoma
06/23
06/23
SGR-1505-101, NCT05544019: Study of SGR-1505 in Mature B-Cell Neoplasms

Recruiting
1
52
US, RoW
SGR-1505
Schrödinger, Inc.
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
03/26
03/26
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Recruiting
1
169
US, RoW
ABSK121-NX
Abbisko Therapeutics Co, Ltd
Solid Tumor
03/25
06/25
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
NCT05828303: A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Withdrawn
1
12
Europe, US, RoW
TPX-0005, repotrectinib, Metformin Hydrochloride, Glucophage, Metabet, Glucient, Diagemet, Axpinet, Digoxin, Lanoxin, Rosuvastatin Calcium, Crestor
Turning Point Therapeutics, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
07/25
11/25
NCT05485974: A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Recruiting
1
44
US
HBI-2438
HUYABIO International, LLC.
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
08/25
08/25
NCT05828277: A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

Withdrawn
1
24
Europe, US
repotrectinib (TPX-0005), Oral TPX-0005 capsules, repotrectinib
Turning Point Therapeutics, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
08/25
12/25
NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Terminated
1
22
US
CHS-006 (anti-TIGIT), JS006, toripalimab (anti-PD-1), CHS-007, TAB001, JS001
Coherus Biosciences, Inc., Medpace, Inc., Shanghai Junshi Bioscience Co., Ltd.
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
07/24
07/24
ON-5001, NCT06022029: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Recruiting
1
168
US, RoW
ONM-501, Cemiplimab, Libtayo
OncoNano Medicine, Inc.
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
04/26
08/26
SHIELD, NCT05117840: Screening for High Frequency Malignant Disease

Active, not recruiting
N/A
12000
Europe, US
Low-dose CT scan
Guardant Health, Inc.
Lung Cancer
12/25
12/25
CYBRID-01, NCT05478538: Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Recruiting
N/A
200
US
Core Needle or Forceps Biopsy
Elephas, Beaufort CRO
Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
12/26
12/26
Dunn, Brittany
No trials found

Download Options